A detailed history of China Universal Asset Management Co., Ltd. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 24,348 shares of HALO stock, worth $1.27 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
24,348
Previous 24,348 -0.0%
Holding current value
$1.27 Million
Previous $990,000 -0.0%
% of portfolio
0.13%
Previous 0.13%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

SELL
$33.68 - $41.95 $1 Million - $1.25 Million
-29,733 Reduced 54.98%
24,348 $990,000
Q4 2023

May 21, 2024

BUY
$33.32 - $42.1 $990,703 - $1.25 Million
29,733 Added 122.12%
54,081 $2 Million
Q4 2023

Jan 23, 2024

SELL
$33.32 - $42.1 $172,031 - $217,362
-5,163 Reduced 8.71%
54,081 $2 Million
Q3 2023

May 21, 2024

BUY
$36.46 - $44.03 $406,091 - $490,406
11,138 Added 23.15%
59,244 $2.26 Million
Q3 2023

Oct 30, 2023

BUY
$36.46 - $44.03 $406,091 - $490,406
11,138 Added 23.15%
59,244 $2.26 Million
Q2 2023

May 21, 2024

BUY
$30.28 - $38.74 $1.15 Million - $1.48 Million
38,094 Added 380.48%
48,106 $1.74 Million
Q2 2023

Jul 27, 2023

BUY
$30.28 - $38.74 $1.15 Million - $1.48 Million
38,094 Added 380.48%
48,106 $1.74 Million
Q1 2023

May 21, 2024

SELL
$32.86 - $55.7 $381,964 - $647,456
-11,624 Reduced 53.73%
10,012 $382,000
Q1 2023

Apr 27, 2023

SELL
$32.86 - $55.7 $381,964 - $647,456
-11,624 Reduced 53.73%
10,012 $382,000
Q4 2022

May 21, 2024

SELL
$40.06 - $59.44 $108,642 - $161,201
-2,712 Reduced 11.14%
21,636 $1.23 Million
Q4 2022

Jan 31, 2023

SELL
$40.06 - $59.44 $132,198 - $196,152
-3,300 Reduced 13.23%
21,636 $1.23 Million
Q3 2022

Oct 21, 2022

BUY
$38.53 - $51.78 $960,784 - $1.29 Million
24,936 New
24,936 $986,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.24B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.